Vaccine to protect animals against leishmania
AssigneesConsejo Superior de Investigaciones Cientificas, Universidad De Zaragoza, Laboratorios Hipra, S.A.
InventorsVicente Emilio Larraga Rodriguez De Vera, Gloria Gonzalez Aseguinolaza, Maria Jesus Ramiro Ibanez, Juan Antonio Castillo Hernandez, Javier Lucientes Curdi
Life of this patent
Estimating the term…
Abstract
The present invention is generally related to the prevention of leishmaniasis in animals, particularly infection caused by Leishmania sp., based on the use of Leishmania infantum P36 protein or an immunogenic fragment of the latter, or involving an expression system for the mentioned protein or fragment—optionally in combination with a compound stimulating the production of a Th1-type cellular immune response—and comprising various vaccination protocols in application to Leishmania sp. based on the mentioned vaccine.
Claims11
A vaccine for protecting an animal from Leishmania infantum infection by an immunization protocol which comprises an initial immunization and a booster dose, said vaccine comprising two separate components:
- (i) soluble Leishmania infantum P 36 protein in a therapeutically effective amount, and
- (ii) a non-Escherichia coli expression system comprising a DNA sequence encoding the Leishmania infantum P36 protein and a DNA sequence encoding interleukin-12, and wherein said expression system provides for the simultaneous expression of said Leishmania infantum P36 protein and interleukin-12, and
- wherein said soluble Leishmania infantum P36 protein is administered to said animal as an initial immunization, and
- said non-Escherichia coli expression system comprising the DNA sequence encoding the Leishmania infantum P36 protein and the DNA sequence encoding interleukin-12 is administered as as a booster dose.
A method of protecting an animal from Leishmania infantum infection, comprising administering to the animal an initial vaccine comprising a first immunogen and a booster vaccine comprising a second immunogen, wherein:
- (i) the first immunogen comprises a soluble Leishmania infantum P36 protein and the second immunogen comprises a non-Escherichia coli expression system comprising a DNA sequence encoding said Leishmania infantum P36 protein and a DNA sequence encoding interleukin-12, wherein said expression system provides for the simultaneous expression of said P36 protein and interleukin-12.
A vaccine for protecting an animal from Leishmania infantum infection by an immunization protocol which comprises an initial immunization and a booster dose, wherein said vaccine comprises two separate components:
- (i) a plasmid which comprises a DNA sequence encoding for L. infantum P36 protein, and (ii) a recombinant Vaccinia virus comprising a DNA sequence encoding for L. infantum P36 protein, wherein
- said plasmid which comprises a DNA sequence encoding for L. infantum P36 protein is administered to said animal as an initial immunization;
- and
- said recombinant Vaccinia virus comprising a DNA sequence encoding for L. infantum P36 protein is administered as a booster dose.
Dependencies are inferred from the claim text.